文献速递呼吸道感染

口服降阶梯治疗、最优药物与抗生素总疗程在非洲重症社区获得性肺炎住院儿童中的研究(PediCAP):一项析因随机对照试验

Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial
RSS 订阅 · PubMed 顶刊 · 肺炎 · 2026-07-23

PediCAP是一项开放标签、平行组、2×5析因随机对照试验,纳入撒哈拉以南非洲五国13家医院2月龄至6岁重症社区获得性肺炎无并发症儿童。结果显示,临床改善后由静脉转为口服阿莫西林、总疗程4-5天的策略,不劣于WHO推荐的5天静脉治疗方案;阿莫西林与阿莫西林-克拉维酸相比无优越性证据。

要点

  • 临床改善后降阶梯为口服阿莫西林、总疗程4-5天,不劣于5天静脉治疗。
  • 阿莫西林-克拉维酸相比阿莫西林无优越性证据(校正风险差1.3% [95%CI -1.8至4.4];p=0.40)。
  • 所有随机疗程均不劣于8天组(所有95%CI上限≤6.0%)。

核心结论

  • 对于撒哈拉以南非洲无并发症的重症社区获得性肺炎住院儿童,临床改善后由静脉抗生素降阶梯为口服阿莫西林、总疗程4-5天的策略,不劣于WHO推荐的5天静脉治疗方案。

研究设计与样本

  • PediCAP为开放标签、平行组、2×5析因随机对照试验,在撒哈拉以南非洲五国13家医院开展。
  • 纳入2月龄至6岁、体重3-30 kg、床旁C反应蛋白超过10 mg/L的重症社区获得性肺炎无并发症住院儿童。
  • 儿童按5:5:1随机分配至静脉转口服阿莫西林(250 mg)或阿莫西林-克拉维酸(阿莫西林200 mg/克拉维酸28.5 mg)分散片每日两次(优效性比较),或5天固定疗程静脉治疗(非劣效性比较)。
  • 总疗程(静脉加口服)分4-8天五个 durations(非劣效性比较);临床改善且能口服时降阶梯。
  • 2020年12月7日至2023年8月14日筛查2248名儿童,随机分配1101名(女480名[43.6%],男621名[56.4%]);主要结局可评估1055名(95.8%)。

主要发现

  • 主要结局(第28天再入院或死亡)发生率:阿莫西林-克拉维酸组33/475(6.9%),阿莫西林组27/484(5.6%),静脉-only组6/96(6.3%);两种口服降阶梯策略均不劣于静脉-only策略(阿莫西林-克拉维酸95%CI上限6.0,阿莫西林95%CI上限5.7)。
  • 阿莫西林-克拉维酸相比阿莫西林无优越性证据:校正风险差1.3%(95%CI -1.8至4.4;p=0.40)。
  • 各疗程组主要结局发生率:4天组8/194(4.1%),5天组10/190(5.3%),6天组16/188(8.5%),7天组16/193(8.3%),8天组10/194(5.2%);所有疗程均不劣于8天组(所有95%CI上限≤6.0%)。
  • 抗生素相关或严重不良事件:静脉-only组1/(1.0%),阿莫西林组12/(2.5%)(校正风险差-2.3% [95%CI -4.2至-0.3];p=0.025),阿莫西林-克拉维酸组16/(3.4%)(+0.8% [-1.2至2.8];p=0.42);发生率随随机疗程延长而增加(斜率估计+0.9% [0.1至1.7];p=0.032)。
  • 降阶梯组平均总抗生素暴露:4天组6.0天(SD 3.5),5天组6.8天(4.2),6天组7.4天(3.6),7天组8.3天(3.4),8天组9.2天(2.9)(p<0.0001);随机疗程内降阶梯比例分别为140/204(68.6%)、151/198(76.3%)、167/196(85.2%)、179/200(89.5%)、186/203(91.6%)(p<0.0001)。

临床怎么用

  • 作者结论认为,对于撒哈拉以南非洲无并发症的重症社区获得性肺炎住院儿童,临床改善后由静脉抗生素降阶梯为口服阿莫西林、总疗程4-5天的策略不劣于WHO推荐的5天静脉治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lancet . 2026 Aug 8;408(10554):545-557. doi: 10.1016/S0140-6736(26)00879-2. Epub 2026 Jul 23. ABSTRACT BACKGROUND: WHO recommends 5 days of intravenous antibiotics for children hospitalised with severe community-acquired pneumonia (CAP). We aimed to investigate the safety of a step-down to different oral antibiotics and the shortest effective duration. METHODS: PediCAP was an open-label, parallel group, 2 × 5 factorial randomised controlled trial of children aged 2 months to 6 years hospitalised with severe CAP without complicating factors in 13 hospitals across five sub-Saharan African countries. Children weighing 3-30 kg and with point-of-care C-reactive protein of more than 10 mg/L were randomly assigned (5:5:1) to either a step-down from intravenous antibiotics to oral amoxicillin (250 mg) or amoxicillin-clavulanate (co-amoxiclav; 200 mg amoxicillin to 28·5 mg clavulanate) via dispersible tablets twice daily (superiority comparison) for five total (intravenous plus oral) durations (4-8 days; non-inferiority comparison), or a 5-day, fixed-duration, intravenous-only treatment (non-inferiority comparison). Children were stepped down when clinically improved and able to take oral antibiotics. Clinicians could change antibiotics if clinically indicated. The primary outcome was the proportion of readmission or death at day 28 (non-inferiority margin vs intravenous only: +10%). The study was registered with the ISRCTN registry (ISRCTN63115131) and is complete. FINDINGS: Between Dec 7, 2020, and Aug 14, 2023, 2248 children were screened for eligibility and 1101 were randomly allocated (480 [43·6%] girls and 621 [56·4%] boys). The primary outcome was available in 1055 (95·8%) children. For children in the step-down groups, the mean total antibiotic exposure was 6·0 days (SD 3·5) in the 4-day group, 6·8 days (4·2) in the 5-day group, 7·4 (3·6) in the 6-day group, 8·3 days (3·4) in the 7-day group, and 9·2 days (2·9) in the 8-day group (p<0·0001), with 140 (68·6%) of 204, 151 (76·3%) of 198, 167 (85·2%) of 196, 179 (89·5%) of 200, and 186 (91·6%) of 203, respectively, stepping down within their randomised duration (p<0·0001). Primary outcomes occurred in 33 (6·9%) of 475 in the co-amoxiclav group, 27 (5·6%) of 484 in the amoxicillin group, and six (6·3%) of 96 in the intravenous-only group, with both oral step-down strategies non-inferior to the intravenous-only strategy (upper 95% CIs of 6·0 for co-amoxiclav and 5·7 for amoxicillin) and no evidence of superiority for co-amoxiclav over amoxicillin (adjusted risk difference 1·3% [95% CI -1·8 to 4·4]; p=0·40). Primary outcomes occurred in eight (4·1%) of 194 in the 4-day group, ten (5·3%) of 190 in the 5-day group, 16 (8·5%) of 188 in the 6-day group, 16 (8·3%) of 193 in the 7-day group, and ten (5·2%) of 194 in the 8-day group; all durations were non-inferior to the 8-day group (all upper 95% CIs ≤6·0%). There was no evidence of consistent differences in adverse events for oral antibiotic or duration comparisons. For antibiotic-related or serious adverse events, there was one (1·0%) in the intravenous-only group and 12 (2·5%) in the amoxicillin group (adjusted risk difference -2·3% [95% CI -4·2 to -0·3]; p=0·025), and 16 (3·4%) in the co-amoxiclav group (+0·8% [-1·2 to 2·8]; p=0·42); rates increased with randomised duration (slope estimate +0·9% [0·1 to 1·7]; p=0·032). Interpretation For sub-Saharan African children hospitalised with severe CAP without complicating factors, a strategy of stepping down upon clinical improvement to oral amoxicillin after initial intravenous antibiotics, with a total treatment duration of 4-5 days, is non-inferior to WHO-recommended 5-day intravenous treatment. Funding The Second European and Developing Countries Clinical Trials Partnership (EDCTP2).

来源:PubMed 顶刊 · 肺炎,查看原文。版权归原作者所有。

引用

  1. PubMed 顶刊 · 肺炎:Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。